Last updated: April 25, 2026
Who Supplies Sovaldi (sofosbuvir) and What Are the Upstream Manufacturing Sources?
Sovaldi (sofosbuvir) is a branded direct-acting antiviral (DAA). In market terms, “suppliers” typically means (1) the original brand manufacturer and (2) the contract manufacturing and API (active pharmaceutical ingredient) supply chain behind it. For Sovaldi, public disclosures consistently tie supply responsibility to Gilead Sciences (brand owner) and to its contract manufacturing network and API suppliers used at different times and geographies.
What company is the brand “supplier” for Sovaldi?
Gilead Sciences, Inc. is the marketing authorization holder/brand owner for Sovaldi (sofosbuvir) in major jurisdictions, and it controls labeling, distribution, and the commercial supply chain through its manufacturing and contracting arrangements.
Which API supplier(s) are used for sofosbuvir?
Public procurement/DMF-based supply chains for sofosbuvir are structured through global API production and controlled substance use. Across the industry, sofosbuvir API supply has been linked to large-scale nucleotide chemistry manufacturers. For business diligence, the key is to map:
- API manufacturer(s) named in regulatory submissions and approvals in target markets
- Drug product manufacturer(s) listed on the local product label/packaging and in approvals
- Contract manufacturers used for tablets/capsules (form/strength specific)
The most reliable path in diligence is to read the manufacturer and distributor fields on the specific market presentation (NDC/MAH packaging, local SmPC package insert, and regulatory EP/US filings), because these change over time and by geography.
Who manufactures the finished drug product (tablets) for Sovaldi?
Finished-dose supply for Sovaldi is produced by contract manufacturing organizations (CMOs) under Gilead’s control, with manufacturer identities varying by region and time. Sovaldi has historically been produced in commercial tablet facilities that support both quality-by-design and cGMP compliance for DAAs.
In diligence, the practical way to identify the manufacturing “supplier” for a given lot is:
- Check the drug product manufacturer printed on the box/bottle
- Match lot/batch release information to the manufacturing site listed on the package insert for that market
How do “suppliers” differ by what you mean (API vs finished dose vs distribution)?
| Supplier role |
What it does in Sovaldi’s chain |
Typical evidence source |
| Brand/MAH supplier |
Controls labeling, distribution, and contracting |
Marketing authorization and label/SmPC/PI |
| API supplier |
Produces sofosbuvir API under controlled processes |
Regulatory submissions, DMF/approval references, inspections |
| Finished-dose manufacturer |
Compresses/encapsulates tablets and performs fill-finish |
Drug product listing on local label/approval |
| Distributor |
Moves product through wholesalers/pharmacies |
Local distribution records, label/distributor fields |
What do you need for decision-grade supplier mapping?
For investment or R&D planning, “supplier list” must be anchored to:
- Target market (US, EU, UK, specific APAC geography)
- Dosage form (Sovaldi tablets)
- Strength and packaging (since supply sites can change across strengths)
- Time window (API and CMO networks evolve)
Without anchoring to a specific jurisdiction and product presentation, a single universal list of “suppliers” is not defensible because the manufacturing site can differ by market and batch.
Key Takeaways
- Gilead Sciences is the brand/marketing authorization holder for Sovaldi (sofosbuvir) and controls the contracting network.
- Sovaldi’s supply chain includes (1) sofosbuvir API production and (2) tablet drug-product manufacture, typically via API manufacturers and CMOs under Gilead oversight.
- Supplier identification must be market- and lot-referenced using label/SmPC/PI manufacturer fields and regulatory references because manufacturers change by region and time.
FAQs
1) Is Gilead the only “supplier” of Sovaldi?
Gilead is the brand owner/MAH. Supply also involves API and finished-dose manufacturers contracted by Gilead.
2) Who makes the sofosbuvir API?
Sofosbuvir API is produced by specialized API manufacturers. The exact named supplier depends on the jurisdiction’s regulatory references and the time period.
3) Who manufactures the finished Sovaldi tablets?
Finished-dose tablet manufacturing is typically performed by contract manufacturing sites listed on the local packaging and regulatory documents for that market.
4) Do Sovaldi manufacturing sites change over time?
Yes. API and CMO networks evolve, and different markets can use different manufacturing sites.
5) What is the most reliable way to identify the supplier for a specific Sovaldi product?
Use the drug product manufacturer printed on the label/packaging for that market presentation and confirm with the corresponding regulatory documentation for that period.
References (APA)
[1] Gilead Sciences, Inc. (n.d.). Sovaldi (sofosbuvir) prescribing information/labeling (market-specific).
[2] European Medicines Agency (EMA). (n.d.). Sovaldi (sofosbuvir) product information (SmPC and related documents).
[3] U.S. Food and Drug Administration (FDA). (n.d.). Sovaldi (sofosbuvir) drug approvals and labeling references.
